Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC010072 | Panoply™ Human NAA10 Knockdown Stable Cell Line | Inquiry |
| CSC-SC010072 | Panoply™ Human NAA10 Over-expressing Stable Cell Line | Inquiry |
| CLOE-0270 | Human NAA10 Insect Cell Lysate | Inquiry |
| CLOE-0273 | Human NAA10(His/GST) Insect Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD10478Z | Human NAA10 adenoviral particles | Inquiry |
| LV19054L | human NAA10 (NM_003491) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH239054 | shRNA set against Rat ARD1A (NM_001135839.1) | Inquiry |
| SHH348748 | shRNA set against Human NAA10 (NM_003491.3) | Inquiry |
| SHH348752 | shRNA set against Mouse NAA10 (NM_019870.3) | Inquiry |
| SHW018405 | shRNA set against Danio rerio NAA10 (NM_213334) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR242974 | Mouse Naa10 ORF Clone(NM_001177965.1) | Inquiry |
| CDFL008109 | Mouse Naa10 cDNA Clone(NM_019870.3) | Inquiry |
| CDFR010209 | Rat Naa10 cDNA Clone(NM_001135839.1) | Inquiry |
| MiUTR3H-02497 | NAA10 miRNA 3'UTR clone | Inquiry |
| CDCB159210 | Human NAA10 ORF clone (BC000308) | Inquiry |
| CDCB179880 | Danio rerio NAA10 ORF Clone (NM_213334) | Inquiry |
| CDCB195116 | Rabbit NAA10 ORF clone (XM_008250281.1) | Inquiry |
| CDCH391252 | Human NAA10 ORF clone(NM_003491.3) | Inquiry |
| CDCR254455 | Mouse Naa10 ORF Clone(NM_019870.3) | Inquiry |
| CDCR275667 | Mouse 4930534B04Rik ORF Clone(NM_181815.3) | Inquiry |
| CDCR377252 | Rat Naa10 ORF Clone(NM_001135839.1) | Inquiry |
| CDCS410027 | Human NAA10 ORF Clone (BC000308) | Inquiry |
| CDCS410028 | Human NAA10 ORF Clone (BC063377) | Inquiry |
Nα-terminal acetylation (NTA) is one of the most common protein modifications that occur during protein synthesis and involves the transfer of an acetyl group from acetyl-coenzyme A to the protein alpha-amino group in many biologic processes. N-terminal acetyltransferase A (NatA) consists of the catalytic subunit Naa10 and the auxiliary subunit Naa15 and acetylates small side chains such as Ser, Ala, Thr, Gly, Val and Cys after the initiator methionine has been cleaved by methionine aminopeptidases.
N-alpha-acetyltransferase 10 (NAA10) is a catalytic subunit of the NatA complex which shows alpha (N-terminal) acetyltransferase activity [1]. The subcellular location of NAA10 is cytoplasm and nucleus. The alpha (N-terminal) acetyltransferase activity may play an important role in vascular, hematopoietic and neuronal growth and development [2].
Gene Function
Fig.1. Multiple functions of Naa10 [7].
The relationships between gene and major human diseases
The relationships between NAA10 and diseases in humans are only recently emerging. For example, many studies combine NAA10 to neurodegenerative disorders, such as Alzheimer’s, Parkinson’s and Huntington’s disease, where abnormal manifestations of single proteins are believed to contribute to disease. Recently, several studies identified mutations of NAA10 in human patients with discrete symptoms, including a craniofacial anomalies, aged appearance, developmental delay, hypotonia, growth retardation and Lenz microphthalmia syndrome. However, the small phenotypic overlap between these patients suggests that different substrates or functions of NAA10 might be affected.
Study has shown that Naa10 binds the cytoplasmic domain of the type I membrane protein β-amyloid precursor protein (APP) and colocalizes with it by its 50 C-terminal amino acids in HEK293 cells [8]. In AD, APP gets processed into beta-amyloid (Aβ) fragments that accumulate into plaques of abnormally folded proteins in the brain. Overexpression of the NatA complex (Naa10 wild type/Naa15 wild type) in HEK293 cells decreases endocytosis of APP and suppresses Aβ40 secretion, whereas the expression of an enzymatic-dead NatA (Naa10 R82A or G85A/Naa15 wild type) attenuated this suppression [8]. However, the mechanism by which NatA regulates Aβ production remains unclear.
NATD is an enzymatic deficiency disease resulting in postnatal growth failure with severe delays and dysmorphic features. Popp et al proposed that N-terminal acetyltransferase deficiency is clinically heterogeneous with the overall catalytic activity determining the phenotypic severity. Casey et al. identified a hemizygous missense mutation in the NAA10 gene [9, 10].
A rare syndrome defined by the canonical features of unilateral or bilateral microphthalmia or anophthalmia and defects in the skeletal and genitourinary systems. The study identified that the NAA10 mutation is the cause of LMS in the diseased family, likely through the dysregulation of the retinoic acid signaling pathway [11].
Conclusions
Most studies have paid attention to the N-terminal activity of NAA10, whereas some findings have been connected to lysine activity and the independent role of NAA10. The goal of future studies will be to elaborate on the cellular/molecular specific activity and distinct pathways of NAA10. Above all, in vivo studies are essential to analyze the definite biological effects of NAA10.
References: